SEC Form 4 · accession 0001104659-15-036796
T2 Biosystems, Inc. · TTOO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael A. Pfaller
Officer — Chief Medical Officer
Period of report
May 8, 2015
Accepted (ET)
May 11, 2015 · 3:56 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001492674
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | May 8, 2015 | M | 15,440 | $10.69 | A | 15,440 | D | |
| Common StockF1 | May 8, 2015 | S | 15,440 | $16.31 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $10.69 | May 8, 2015 | M | 15,440 | A | — | Apr 9, 2024 | Common Stock | 15,440 | 37,501 | D |
Explanation of responses
- F1The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $15.90 to $ 16.40. The reporting person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F2This Stock Option was granted on April 9, 2014 and vesting commenced on March 3, 2014. Options to purchase 25% of the total underlying shares vested on the first anniversary of the vesting commencement date and options to purchase the remaining shares vest in 36 equal monthly installments thereafter.